Aardvark Therapeutics Inc
NASDAQ:AARD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Aardvark Therapeutics Inc
Cash from Investing Activities
Aardvark Therapeutics Inc
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Aardvark Therapeutics Inc
NASDAQ:AARD
|
Cash from Investing Activities
-$49.7m
|
CAGR 3-Years
-268%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Investing Activities
-$23.6B
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-12%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Investing Activities
-$4.1B
|
CAGR 3-Years
-57%
|
CAGR 5-Years
18%
|
CAGR 10-Years
-10%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Investing Activities
-$1.4B
|
CAGR 3-Years
56%
|
CAGR 5-Years
21%
|
CAGR 10-Years
8%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Investing Activities
-$13.7B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Investing Activities
-$11B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
Aardvark Therapeutics Inc
Glance View
Aardvark Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in San Diego, California and currently employs 18 full-time employees. The company went IPO on 2025-02-13. The firm targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. The company is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).
See Also
What is Aardvark Therapeutics Inc's Cash from Investing Activities?
Cash from Investing Activities
-49.7m
USD
Based on the financial report for Dec 31, 2025, Aardvark Therapeutics Inc's Cash from Investing Activities amounts to -49.7m USD.
What is Aardvark Therapeutics Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
-268%
Over the last year, the Cash from Investing Activities growth was -314%. The average annual Cash from Investing Activities growth rates for Aardvark Therapeutics Inc have been -268% over the past three years .
